ofloxacin has been researched along with Blood Poisoning in 38 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open, randomized, multinational, multicentre study was conducted to compare the efficacy, safety and tolerability of levofloxacin 500 mg twice daily with imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized adult patients with clinically suspected bacteraemia/ sepsis." | 9.09 | Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. ( Geddes, A; Härkönen, M; Jacobs, F; Nowotny, I; Schonwald, S; Thaler, M, 1999) |
| " To this day, no other case of prostatic abscess due to this strain but susceptible to methicillin has been described." | 7.80 | Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin. ( Barraud, O; Brakbi, Y; Cypierre, A; Dubos, M; Fedou, AL; François, B; Fredon, F; Laurent, F, 2014) |
| "A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 7.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
| "Fluoroquinolones are the most commonly used prophylactic antimicrobials for ultrasound-guided transrectal prostate biopsy due to their broad pathogen spectrum, pharmacokinetics, bioavailability and ease of oral administration." | 6.44 | Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. ( Fujisawa, M; Miura, T; Nakano, Y; Shigemura, K; Takenaka, A; Tanaka, K, 2008) |
| "These results suggest that tandem cycles of concurrent 96-h infusions of dexrazoxane and high-dose doxorubicin can be administered with minimal cardiac toxicity, and have activity in patients with recurrent sarcomas." | 5.11 | Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. ( Al-Khadimi, Z; Chow, WA; Doroshow, JH; Frankel, P; Lawrence, J; Leong, L; Lim, D; Longmate, J; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Twardowski, P; Yen, Y, 2004) |
| "An open, randomized, multinational, multicentre study was conducted to compare the efficacy, safety and tolerability of levofloxacin 500 mg twice daily with imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized adult patients with clinically suspected bacteraemia/ sepsis." | 5.09 | Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. ( Geddes, A; Härkönen, M; Jacobs, F; Nowotny, I; Schonwald, S; Thaler, M, 1999) |
| "To compare the cost-effectiveness of sequential intravenous-to-oral ofloxacin versus intravenous-to-oral standard switch therapy for the treatment of patients with sepsis who are hospitalized with bacterial infections." | 5.08 | Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy. ( Paladino, JA; Partsch, DJ, 1997) |
| " To this day, no other case of prostatic abscess due to this strain but susceptible to methicillin has been described." | 3.80 | Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin. ( Barraud, O; Brakbi, Y; Cypierre, A; Dubos, M; Fedou, AL; François, B; Fredon, F; Laurent, F, 2014) |
| "A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 3.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
| "In a fibrin-clot model of sepsis, developed in mice, treatment with the antibiotics ceftazidime (Cfz) and ofloxacin (Ofl) caused significant (p < 0." | 3.73 | Antibiotic-induced release of inflammatory mediators from bacteria in experimental Klebsiella pneumoniae-induced sepsis. ( Bramhne, HG; Chhibber, S; Sharma, S; Toky, V, 2005) |
| " These differences can pose challenges in developing appropriate dosing guidelines." | 2.72 | Do intensive care patients need an individualized dosing regimen for levofloxacin? ( Barth, J; Hochhaus, G; Jäger, D; Kaufmann, S; Tayab, ZR, 2006) |
| " Dosage adjustment was made for patients in renal failure." | 2.67 | Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients. ( Beaucaire, G; Beuscart, C; Chidiac, C; Leroy, O; Mouton, Y; Senneville, E; Sivery, B; Vincent du Laurier, M, 1990) |
| "Ofloxacin was administered at a dose of 200 mg every 12 hours for a mean duration of ten days." | 2.66 | [Efficacy of injectable ofloxacin in treating septicemia. Multicenter study]. ( Doco-Lecompte, T; Modaï, J, 1989) |
| "Fluoroquinolones are the most commonly used prophylactic antimicrobials for ultrasound-guided transrectal prostate biopsy due to their broad pathogen spectrum, pharmacokinetics, bioavailability and ease of oral administration." | 2.44 | Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. ( Fujisawa, M; Miura, T; Nakano, Y; Shigemura, K; Takenaka, A; Tanaka, K, 2008) |
| "Septic pulmonary embolism (SPE) is an uncommon, but life-threatening event that is usually associated with extrapulmonary infections." | 1.37 | Tsukamurella tyrosinosolvens and Rhizobium radiobacter sepsis presenting with septic pulmonary emboli. ( Calista, F; Fadda, G; Fiori, B; Mignogna, S; Romano, L; Sali, M; Spanu, T; Zappacosta, B, 2011) |
| "Sepsis was diagnosed in 17 patients (3." | 1.37 | Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. ( Akduman, B; Akduman, D; Ayoğlu, F; Erol, B; Mungan, NA; Tokgöz, H; Türker, T, 2011) |
| "Treatment with levofloxacin could not prevent abortion." | 1.33 | An unusual cause of sepsis during pregnancy: recognizing infection with chlamydophila abortus. ( Brezinka, C; Gritsch, W; Hotzel, H; Ploner, F; Tauber, R; Walder, G; Würzner, R, 2005) |
| " In these strains, levofloxacin ED(50)s were 2- to 10-fold lower than the ED(50)/MIC ratios in the other strains and 90% E(max) AUC/MIC ratios were 2- to 4-fold lower than those predicted from pharmacodynamic modeling of efficacy against other strains." | 1.33 | Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? ( Cho, D; Corcoran, E; Dudley, MN; Griffith, DC; Lee, A; Lofland, D; Lomovskaya, O, 2006) |
| " In addition to standard pharmacokinetic parameters, the total dialysate concentration of both drugs was measured using a technically simple single-pass batch dialysis system for EDD." | 1.33 | Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. ( Czock, D; de Groot, K; Fliser, D; Hafer, C; Haller, H; Hüsig-Linde, C; Keller, F; Kielstein, JT; Kuse, E; Langhoff, A; Schöpke, T; Swoboda, S, 2006) |
| "The first case of septicemia due to Yersinia pseudotuberculosis in an HIV-infected person was reported." | 1.32 | Short Communication: Yersinia pseudotuberculosis septicemia in an HIV-infected patient failed HAART. ( Alba, L; Antinori, A; Boumis, E; Festa, A; Marconi, P; Paglia, MG; Pucillo, LP; Visca, P, 2004) |
| "Treatment with ofloxacin and ciprofloxacin at 50 mg/kg 18 h after infection did not significantly increase survival rates compared with those of untreated controls." | 1.28 | Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. ( Azoulay-Dupuis, E; Bedos, JP; Hardy, DJ; Pocidalo, JJ; Swanson, RN; Vallée, E, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.26) | 18.7374 |
| 1990's | 8 (21.05) | 18.2507 |
| 2000's | 21 (55.26) | 29.6817 |
| 2010's | 7 (18.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubos, M | 1 |
| Barraud, O | 1 |
| Fedou, AL | 1 |
| Fredon, F | 1 |
| Laurent, F | 1 |
| Brakbi, Y | 1 |
| Cypierre, A | 1 |
| François, B | 1 |
| Green, O | 1 |
| Murray, P | 1 |
| Gea-Banacloche, JC | 1 |
| Sarullo, FM | 1 |
| Americo, L | 1 |
| Accardo, S | 1 |
| Cicero, S | 1 |
| Schicchi, R | 1 |
| Schirò, M | 1 |
| Castello, A | 1 |
| Gupta, A | 2 |
| Khaira, A | 1 |
| Bhalla, AK | 1 |
| Rana, DS | 1 |
| Romano, L | 1 |
| Spanu, T | 1 |
| Calista, F | 1 |
| Zappacosta, B | 1 |
| Mignogna, S | 1 |
| Sali, M | 1 |
| Fiori, B | 1 |
| Fadda, G | 1 |
| Akduman, B | 1 |
| Akduman, D | 1 |
| Tokgöz, H | 1 |
| Erol, B | 1 |
| Türker, T | 1 |
| Ayoğlu, F | 1 |
| Mungan, NA | 1 |
| Loeb, S | 1 |
| Manecksha, RP | 1 |
| Nason, GJ | 1 |
| Cullen, IM | 1 |
| Fennell, JP | 1 |
| McEvoy, E | 1 |
| McDermott, T | 1 |
| Flynn, RJ | 1 |
| Grainger, R | 1 |
| Thornhill, JA | 1 |
| Parra-Riffo, H | 1 |
| Lemus-Peñaloza, J | 1 |
| Georgescu, V | 1 |
| Lespessailles, E | 1 |
| Martin, L | 1 |
| Poisson, DM | 1 |
| Estève, E | 1 |
| Zeitlinger, MA | 1 |
| Dehghanyar, P | 1 |
| Mayer, BX | 1 |
| Schenk, BS | 1 |
| Neckel, U | 1 |
| Heinz, G | 1 |
| Georgopoulos, A | 1 |
| Müller, M | 1 |
| Joukhadar, C | 1 |
| Nakayama, K | 1 |
| Ishida, Y | 1 |
| Ohtsuka, M | 1 |
| Kawato, H | 1 |
| Yoshida, K | 2 |
| Yokomizo, Y | 1 |
| Ohta, T | 1 |
| Hoshino, K | 2 |
| Otani, T | 1 |
| Kurosaka, Y | 1 |
| Ishida, H | 1 |
| Lee, VJ | 1 |
| Renau, TE | 1 |
| Watkins, WJ | 1 |
| Candel, FJ | 1 |
| Roca-Arbonés, V | 1 |
| Núñez, MJ | 1 |
| Arroyo, C | 1 |
| Valdivia, A | 1 |
| Téllez, MJ | 1 |
| Picazo, JJ | 1 |
| Chow, WA | 1 |
| Synold, TW | 1 |
| Tetef, ML | 1 |
| Longmate, J | 1 |
| Frankel, P | 1 |
| Lawrence, J | 1 |
| Al-Khadimi, Z | 1 |
| Leong, L | 1 |
| Lim, D | 1 |
| Margolin, K | 1 |
| Morgan, RJ | 1 |
| Raschko, J | 1 |
| Shibata, S | 1 |
| Somlo, G | 1 |
| Twardowski, P | 1 |
| Yen, Y | 1 |
| Doroshow, JH | 1 |
| Antinori, A | 1 |
| Paglia, MG | 1 |
| Marconi, P | 1 |
| Festa, A | 1 |
| Alba, L | 1 |
| Boumis, E | 1 |
| Pucillo, LP | 1 |
| Visca, P | 1 |
| Bauhofer, A | 1 |
| Celik, I | 1 |
| Plaul, U | 1 |
| Wulf, H | 1 |
| Torossian, A | 1 |
| Alkorta, M | 1 |
| Giménez, MJ | 1 |
| Vicente, D | 1 |
| Aguilar, L | 1 |
| Pérez-Trallero, E | 1 |
| Toky, V | 1 |
| Sharma, S | 1 |
| Bramhne, HG | 1 |
| Chhibber, S | 1 |
| Walder, G | 1 |
| Hotzel, H | 1 |
| Brezinka, C | 1 |
| Gritsch, W | 1 |
| Tauber, R | 1 |
| Würzner, R | 1 |
| Ploner, F | 1 |
| Ruotsalainen, E | 1 |
| Järvinen, A | 1 |
| Koivula, I | 1 |
| Kauma, H | 1 |
| Rintala, E | 1 |
| Lumio, J | 1 |
| Kotilainen, P | 1 |
| Vaara, M | 1 |
| Nikoskelainen, J | 1 |
| Valtonen, V | 1 |
| Griffith, DC | 1 |
| Corcoran, E | 1 |
| Lofland, D | 1 |
| Lee, A | 1 |
| Cho, D | 1 |
| Lomovskaya, O | 1 |
| Dudley, MN | 1 |
| Tayab, ZR | 1 |
| Hochhaus, G | 1 |
| Kaufmann, S | 1 |
| Jäger, D | 1 |
| Barth, J | 1 |
| Ozkan, S | 1 |
| Akay, T | 1 |
| Randhawa, VS | 1 |
| Kumar, A | 1 |
| Saili, A | 1 |
| Datta, V | 1 |
| Agrawal, C | 1 |
| Mehta, G | 1 |
| Czock, D | 1 |
| Hüsig-Linde, C | 1 |
| Langhoff, A | 1 |
| Schöpke, T | 1 |
| Hafer, C | 1 |
| de Groot, K | 1 |
| Swoboda, S | 1 |
| Kuse, E | 1 |
| Haller, H | 1 |
| Fliser, D | 1 |
| Keller, F | 1 |
| Kielstein, JT | 1 |
| Miura, T | 1 |
| Tanaka, K | 1 |
| Shigemura, K | 1 |
| Nakano, Y | 1 |
| Takenaka, A | 1 |
| Fujisawa, M | 1 |
| Klesel, N | 1 |
| Geweniger, KH | 1 |
| Koletzki, P | 1 |
| Isert, D | 1 |
| Limbert, M | 1 |
| Markus, A | 1 |
| Riess, G | 1 |
| Schramm, H | 1 |
| Iyer, P | 1 |
| Partsch, DJ | 1 |
| Paladino, JA | 1 |
| Geddes, A | 1 |
| Thaler, M | 1 |
| Schonwald, S | 1 |
| Härkönen, M | 1 |
| Jacobs, F | 1 |
| Nowotny, I | 1 |
| Lin, FY | 1 |
| Azimi, PH | 1 |
| Weisman, LE | 1 |
| Philips, JB | 1 |
| Regan, J | 1 |
| Clark, P | 1 |
| Rhoads, GG | 1 |
| Clemens, J | 1 |
| Troendle, J | 1 |
| Pratt, E | 1 |
| Brenner, RA | 1 |
| Gill, V | 1 |
| Inoue, M | 1 |
| Kuga, A | 1 |
| Kaieda, S | 1 |
| Hosaka, M | 1 |
| Kitasato, H | 1 |
| Sato, Y | 1 |
| Okamoto, R | 1 |
| Eda, T | 1 |
| Seto, I | 1 |
| Brook, I | 2 |
| Ledney, GD | 2 |
| Azoulay-Dupuis, E | 1 |
| Bedos, JP | 1 |
| Vallée, E | 1 |
| Hardy, DJ | 1 |
| Swanson, RN | 1 |
| Pocidalo, JJ | 1 |
| Lode, H | 1 |
| Wiley, E | 1 |
| Olschewski, P | 1 |
| Sievers, H | 1 |
| Wintermantel, M | 1 |
| Baetz, R | 1 |
| Lebahn, K | 1 |
| Reinke, M | 1 |
| Wagner, J | 1 |
| Borner, K | 1 |
| Mouton, Y | 1 |
| Leroy, O | 1 |
| Beuscart, C | 1 |
| Sivery, B | 1 |
| Senneville, E | 1 |
| Chidiac, C | 1 |
| Beaucaire, G | 1 |
| Vincent du Laurier, M | 1 |
| Doco-Lecompte, T | 1 |
| Modaï, J | 1 |
| Umeki, S | 1 |
| Okamoto, Y | 1 |
| Hisamoto, N | 1 |
| Hara, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00548002] | 430 participants (Actual) | Observational | 1999-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ofloxacin and Blood Poisoning
| Article | Year |
|---|---|
Severe levofloxacin-induced hypoglycaemia: a case report and literature review.
Topics: Aged; Anti-Bacterial Agents; Catheter-Related Infections; Drug Therapy, Combination; Enterococcus; G | 2012 |
Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Biopsy; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli | 2008 |
8 trials available for ofloxacin and Blood Poisoning
| Article | Year |
|---|---|
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Topics: Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Drug Administration Schedule | 2004 |
Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Chi-Square Distribution; Drug Therapy, Combination; | 2006 |
Do intensive care patients need an individualized dosing regimen for levofloxacin?
Topics: Anti-Bacterial Agents; Critical Illness; Female; Humans; Intensive Care Units; Levofloxacin; Male; M | 2006 |
Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Cost-Benefit Analysis; Delivery of Health C | 1997 |
Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Cilastatin; Cilastati | 1999 |
Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.
Topics: Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Clavulanic Acids; Drug Combination | 1990 |
Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Female; Fran | 1990 |
[Efficacy of injectable ofloxacin in treating septicemia. Multicenter study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Gram-Negative Bacteria; Humans; Injections, Intr | 1989 |
28 other studies available for ofloxacin and Blood Poisoning
| Article | Year |
|---|---|
Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin.
Topics: Abscess; Bacterial Toxins; Exotoxins; Humans; Leukocidins; Magnetic Resonance Imaging; Male; Methici | 2014 |
Sepsis caused by Elizabethkingia miricola successfully treated with tigecycline and levofloxacin.
Topics: Anti-Bacterial Agents; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxa | 2008 |
Tako-tsubo cardiomyopathy observed in a patient with sepsis and transient hyperthyroidism.
Topics: Amlodipine; Anti-Bacterial Agents; Antihypertensive Agents; Antithyroid Agents; Aspirin; Echocardiog | 2009 |
Chryseobacterium septicemia in a renal allograft recipient.
Topics: Bronchopneumonia; Chryseobacterium; Flavobacteriaceae Infections; Humans; Kidney Transplantation; Ma | 2010 |
Tsukamurella tyrosinosolvens and Rhizobium radiobacter sepsis presenting with septic pulmonary emboli.
Topics: Actinomycetales; Actinomycetales Infections; Aged; Agrobacterium tumefaciens; Anti-Bacterial Agents; | 2011 |
Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy, Needle; Drug Resistance, Bacterial; Flu | 2011 |
Editorial comment.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy, Needle; Drug Resistance, Bacterial; Fluoroqui | 2011 |
Prospective study of antibiotic prophylaxis for prostate biopsy involving >1100 men.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Cephalosporins; Drug Resistance, Bacter | 2012 |
[Digital purpura revealing septicaemical rat-bite fever].
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Arthritis, Infectious; Diagnosis, Differential; | 2002 |
Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.
Topics: Aged; Anti-Infective Agents; Area Under Curve; Blood Proteins; Drug Delivery Systems; Female; Humans | 2003 |
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.
Topics: Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Biological Transport, Active; Car | 2003 |
A rare cause of pericarditis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; HIV Infections; HIV-1; Humans; | 2003 |
Short Communication: Yersinia pseudotuberculosis septicemia in an HIV-infected patient failed HAART.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Ceftriaxone; Dr | 2004 |
Effects of G-CSF and antibiotic prophylaxis in a 2 x 2 factorial design on outcome in septic rats.
Topics: Abdomen; Animals; Antibiotic Prophylaxis; Cefuroxime; Clinical Trials as Topic; Disease Models, Anim | 2004 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DN | 2005 |
Antibiotic-induced release of inflammatory mediators from bacteria in experimental Klebsiella pneumoniae-induced sepsis.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Disease Models, Animal; Endotoxins; Humans; I | 2005 |
An unusual cause of sepsis during pregnancy: recognizing infection with chlamydophila abortus.
Topics: Abortion, Spontaneous; Adult; Animals; Chlamydophila psittaci; Female; Goat Diseases; Goats; Humans; | 2005 |
Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Outer Membrane Proteins; Disease Models, | 2006 |
Diaphragm paralysis in children after cardiac surgery.
Topics: Anti-Bacterial Agents; Cardiac Surgical Procedures; Cefazolin; Diaphragm; Female; Heart Defects, Con | 2007 |
Paratyphoid sepsis.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Bottle Feeding; Breast Feeding; Cesarean Section; Female; Fo | 2007 |
Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Anuria; Aza Compounds; Critical Care; Criti | 2006 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Kle | 1995 |
Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998.
Topics: Anti-Bacterial Agents; Bacterial Capsules; Cefotaxime; Chloramphenicol; Clindamycin; Drug Resistance | 2000 |
[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Humans; L | 2000 |
Short and long courses of ofloxacin therapy of Klebsiella pneumoniae sepsis following irradiation.
Topics: Animals; Cobalt Radioisotopes; Drug Administration Schedule; Female; Ileum; Immunocompromised Host; | 1992 |
Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Erythromycin; Fe | 1991 |
Oral ofloxacin therapy of Pseudomonas aeruginosa sepsis in mice after irradiation.
Topics: Animals; Cobalt Radioisotopes; Female; Ileum; Liver; Mice; Mice, Inbred Strains; Microbial Sensitivi | 1990 |
[Development of Aeromonas hydrophila septicemia in a young healthy woman].
Topics: Adult; Aeromonas; Bacterial Infections; Drug Therapy, Combination; Female; Humans; Moxalactam; Oflox | 1988 |